公开(公告)号：EP4006051A1

公开(公告)日：2022-06-01

申请号：EP21189336.7

申请日：2016-03-08

申请人： Argenx BVBA

发明人： ONGENAE, Nicolas, G.h ,  DREIER, Torsten ,  ULRICHTS, Peter ,  DE HAARD, Johannes ,  BLANCHETOT, Christophe

IPC分类号： C07K16/00 ,  A61K38/17 ,  A61K45/06 ,  C07K16/28 ,  C07K16/40 ,  C07K14/47 ,  A61K39/00 ,  A61P21/04 ,  A61P25/00 ,  A61P25/08 ,  A61P43/00 ,  A61P7/00 ,  A61P37/06

摘要： Provided are novel methods of reducing the serum levels of Fc-containing agents (e.g., antibodies and immunoadhesins) in a subject. These methods generally comprise administering to the subject an effective amount of an isolated FcRn-antagonist that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. The disclosed methods are particularly useful for treating antibody-mediated disorders (e.g. autoimmune diseases).